Application Number Filing Date INFORMATION DISCLOSURE First Named Inventor STATEMENT BY APPLICANT

10805831 2004-03-22 Mary E. Alwin Art Unit 1742 Examiner Name Sikyin Ip Attorney Docket Number 201141 00003

U.S.PATENT

(Not for submission under 37 CFR 1.99)

U.S.PATENTS								
Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
1	6536504		2003-03-25	Takeuchi et al.				
2	5584337		1996-12-17	Nakashima et al.				
3	5651412		1997-07-29	Williams et al.				
4	5720335		1998-02-24	Osada et al.				
	1 2 3	No Patent Number 1 6538504 2 5584337 3 5651412	No Patent Number Code1 1 8536504 2 5584337 3 5651412	Cite No Patent Number Kind Code Issue Date 1 6536504 2003-03-25 2 5584337 1996-12-17 3 5651412 1997-07-29	Cite No Patent Number Kind Code Issue Date Name of Patentee or Applicant of cited Document 1 8538504 2003-03-25 Takeuch et al. 2 5584337 1998-12-17 Nakachima et al. 3 5651412 1997-07-29 Williams et al.			

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS

U.S.FAIENI AFFEIGAIR					A IENI AFFLI	CATION FUBLICATIONS	
	Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
		1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

	FOREIGN PATENT DOCUMENTS							
Exami Initial*	ner Cite No	Foreign Document Number ³	Country Code ² i	Kind Code4	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	TK

STATEMENT BY APPLICANT	i ii st i tainied in tenior		L /umii	
(Not for submission under 37 CFR 1.99)	Art Unit		1742	
,	Examiner Name	xaminer Name Sikyin Ip		
	Attorney Docket Numb	er	201141.00093	
				_

	1	03/023074	wo		2003-03-20	AK Properties, Inc.		
--	---	-----------	----	--	------------	---------------------	--	--

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	Τs							
	1	International Search Report for PCT/AU2005/000402								

If you wish to add additional non-patent literature document citation information please click the Add button

Examiner Signature Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kind Codes of USPTO Patent Documents at twenUSPTO.00V or MIPP 9010A. I Enter office that issued the document, by the two-letter order (WIPO Standard ST3.). I "For Japanese patent document, the inclusion of the parent or the representation processed the seeks included or the parent of the parent or the parent order. I will not comment by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if Emplois languages retriated in a standard.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10805831
Filing Date		2004-03-22
First Named Inventor Mary		E. Alwin
Art Unit		1742
Examiner Name	Sikyir	ı İp
Attorney Docket Number		201141.00093

CERTIFICATION STATEMENT

Diagon con 3	7 CEP	1 07 and	1.98 to make th	na annonoriata	ealaction(e)

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(a)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tem of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.59(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.39(c) and the statement. See 37 CFR 1.39(c) and the statement. See 37 CFR 1.39(c) and the statement. See 37 CFR 1.39(c) are statement. See

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Michael H. Minns/	Date (YYYY-MM-DD)	2006-12-21
Name/Print	Michael H. Minns	Registration Number	31985

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$51.US. C12.04 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant Artificia, U.S. Department of Commence, P. D. 8b. 1450, Alexandri, V.S. 2231-1450, D. ROY SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patients, P.O. Box 1450, Alexandria, V.S. 2231-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicide is coultainly, and (3) the principal purpuses for which the information is used by the U.S. Patient and Trademark Office is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested information is used to be able to process and/or examine your submission, which may information, they C.S. Potent and Trademark Office may not be able to process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing coursel in the course of settlement negotiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, unusuant to 5 U.S. 5524m.)
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be discbeed, as a noutine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make reterminations about individuals.
- 3. A record from this system of records may be disclosed, as a routine use, be the public after either publication of the application pursuant to 55 U.S.C. 12(b) or issuance of a patient pursuant to 55 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.